Ipilimumab and pembrolizumab are biologic immunotherapy agents that have been approved by the FDA for treating metastatic melanoma .
Therapies for metastatic melanoma include biologic immunotherapy agents ipilimumab , pembrolizumab , and nivolumab ; BRAF inhibitors , such as vemurafenib and dabrafenib ; and a MEK inhibitor trametinib.
Melanoma